Bristol-myers Squibb Compnay

Viiv Healthcare UK (no.5) Limited

Innate Tumor Immunity, Inc.

Prasanna Sivaprakasam

Sanjeev Gangwar

Yam B Poudel

Liqi He

Shoshana L Posy

John E Macor

Gene Michael Dubowchik

Guanglin Luo

John F Kadow

B Narasimhulu Naidu

Kevin M Peese

Ashvinikumar V Gavai

Shomir Ghosh

Qian Zhang

Naidu S Chowdari

Ling Chen

Swanee E Jacutin-Porte

Manoj Patel

Ivar M McDonald

Richard A Hartz

Heng Cheng

Vijay T Ahuja

Christiana I Iwuagwu

Ian Scott Young

William R Roush

Steven P Seitz

Yong Zhang

Kyle E Parcella

Jay A Markwalder

Christine M Tarby

Kyle J Eastman

Ashok Vinayak Purandare

Yong Tu

Vivekananda M Vrudhula

Zhongyu Wang

Honghe Wan

Matthew Cox

Andrew Forrest Donnell

Senliang Pan

Matthias Broekema

Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.

1-pyrazolo[4,3-]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists

The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

NLRP3 modulators

1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor

Compounds having a structure according to formula are modulators of TLR7 activity and can be used to treat conditions amenable to treatment by the modulation of TLR7 activity. 

Macrocyclic toll-like receptor 7 (TLR7) agonists

Compounds according to formula II are useful as agonists of Toll-like receptor 7 (TLR7).  Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.

2H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3. 

Pyrimidine carboxamides as GSK-3 inhibitors

Compounds having a structure according to formula (I), (II), or (III) where R, R, R, RX, X, and Xare as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.

Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor

Compounds having a structure according to formula (I) where R, R, and Rare as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.

Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor

Compounds having a structure according to formula (I) or (II) where R, R, and Ar are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.

Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor

Compounds having a structure according to formula (I) where Rand Ar are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.

Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor

Compounds having a structure according to formula (I) or (II) where R, R, R, R, Ar and Xare as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.

Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor

A compound capable of inhibiting cell proliferation, having a structure according to formula (I) wherein the variables in formula (I) are as defined in the specification. Such compounds are useful as anti-cancer agents, especially in antibody-drug conjugates.

Antiproliferative compounds and conjugates made therefrom

The disclosure generally relates to compounds of formula (I), including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3. 

GSK-3 inhibitors

Growing community of inventors

Lawrenceville, NJ, United States of America

Prasanna Sivaprakasam